283 related articles for article (PubMed ID: 29477343)
1. T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation.
Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
Clin Immunol; 2018 May; 190():32-40. PubMed ID: 29477343
[TBL] [Abstract][Full Text] [Related]
2. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
[TBL] [Abstract][Full Text] [Related]
3. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
[TBL] [Abstract][Full Text] [Related]
5. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.
Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Zhu L; Zeng H; Schell TD; Zheng H
Blood Cancer J; 2015 Jul; 5(7):e330. PubMed ID: 26230954
[TBL] [Abstract][Full Text] [Related]
6. Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse.
Sobiak J; Kazimierczak U; Kowalczyk DW; Chrzanowska M; Styczyński J; Wysocki M; Szpecht D; Wachowiak J
Arch Immunol Ther Exp (Warsz); 2015 Oct; 63(5):385-95. PubMed ID: 26040247
[TBL] [Abstract][Full Text] [Related]
7. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
[TBL] [Abstract][Full Text] [Related]
8. [Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].
Ai H; Yin QS; Wang Q; Fu YW; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):239-244. PubMed ID: 32311895
[No Abstract] [Full Text] [Related]
9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia.
Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia.
Bai L; Cheng YF; Lu AD; Suo P; Wang Y; Zuo YX; Yan CH; Wu J; Jia YP; Sun YQ; Chen YH; Chen H; Liu KY; Han W; Xu LP; Wang JB; Tang XF; Chen HR; Zhang LP; Huang XJ
Leuk Res; 2020 Apr; 91():106333. PubMed ID: 32109757
[TBL] [Abstract][Full Text] [Related]
12. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.
Noviello M; Manfredi F; Ruggiero E; Perini T; Oliveira G; Cortesi F; De Simone P; Toffalori C; Gambacorta V; Greco R; Peccatori J; Casucci M; Casorati G; Dellabona P; Onozawa M; Teshima T; Griffioen M; Halkes CJM; Falkenburg JHF; Stölzel F; Altmann H; Bornhäuser M; Waterhouse M; Zeiser R; Finke J; Cieri N; Bondanza A; Vago L; Ciceri F; Bonini C
Nat Commun; 2019 Mar; 10(1):1065. PubMed ID: 30911002
[TBL] [Abstract][Full Text] [Related]
14. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.
Bader P; Rossig C; Hutter M; Ayuk FA; Baldus CD; Bücklein VL; Bonig H; Cario G; Einsele H; Holtick U; Koenecke C; Bakhtiar S; Künkele A; Meisel R; Müller F; Müller I; Penack O; Rettinger E; Sauer MG; Schlegel PG; Soerensen J; von Stackelberg A; Strahm B; Hauer J; Feuchtinger T; Jarisch A
Blood Adv; 2023 Jun; 7(11):2436-2448. PubMed ID: 36607834
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation.
Simonetta F; Pradier A; Bosshard C; Masouridi-Levrat S; Dantin C; Koutsi A; Tirefort Y; Roosnek E; Chalandon Y
Front Immunol; 2019; 10():1034. PubMed ID: 31156625
[TBL] [Abstract][Full Text] [Related]
16. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Cui JK; Xiao Y; You Y; Shi W; Li Q; Luo Y; Jiang L; Zhong ZD
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):693-698. PubMed ID: 29058281
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation.
Li Z; Wang J; Deng L; Liu X; Kong F; Zhao Y; Hou Y; Zhou F
Front Immunol; 2024; 15():1382099. PubMed ID: 38665912
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells.
Adachi Y; Sakai T; Terakura S; Shiina T; Suzuki S; Hamana H; Kishi H; Sasazuki T; Arase H; Hanajiri R; Goto T; Nishida T; Murata M; Kiyoi H
Int J Hematol; 2022 Mar; 115(3):371-381. PubMed ID: 35037229
[TBL] [Abstract][Full Text] [Related]
19. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
20. Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation.
Jiang Y; Wan L; Qin Y; Wang X; Yan S; Xie K; Wang C
PLoS One; 2015; 10(7):e0133671. PubMed ID: 26226104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]